AstraZeneca: ZS-9 gets positive opinion in Europe.

(CercleFinance.com) - AstraZeneca said the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of ZS-9 for the treatment of hyperkalaemia.


Hyperkalaemia is a serious condition characterised by high potassium levels in the blood serum caused by cardiovascular, renal and metabolic diseases.

Results from a phase III study showed that in patients with hyperkalaemia, sodium zirconium cyclosilicate (ZS-9) significantly reduced blood serum potassium to normal levels within 48 hours.

ZS-9 has been developed by ZS Pharma, a US biotech company which was bought by AstraZeneca in November 2015.

Copyright (c) 2017 CercleFinance.com. All rights reserved.